JP2019531745A - 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター - Google Patents

主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター Download PDF

Info

Publication number
JP2019531745A
JP2019531745A JP2019520801A JP2019520801A JP2019531745A JP 2019531745 A JP2019531745 A JP 2019531745A JP 2019520801 A JP2019520801 A JP 2019520801A JP 2019520801 A JP2019520801 A JP 2019520801A JP 2019531745 A JP2019531745 A JP 2019531745A
Authority
JP
Japan
Prior art keywords
vector
cmv
mhc
antigen
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019520801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531745A5 (https=
Inventor
ネルソン、ジェイ
マルーリ、ダニエル
ピッカー、ルイス
ハンコック、ミーガン
サチャ、ジョナー
フルー、クラウス
ハンセン、スコット
Original Assignee
オレゴン ヘルス アンド サイエンス ユニバーシティ
オレゴン ヘルス アンド サイエンス ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレゴン ヘルス アンド サイエンス ユニバーシティ, オレゴン ヘルス アンド サイエンス ユニバーシティ filed Critical オレゴン ヘルス アンド サイエンス ユニバーシティ
Publication of JP2019531745A publication Critical patent/JP2019531745A/ja
Publication of JP2019531745A5 publication Critical patent/JP2019531745A5/ja
Priority to JP2022169043A priority Critical patent/JP7478794B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019520801A 2016-10-18 2017-10-18 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター Pending JP2019531745A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022169043A JP7478794B2 (ja) 2016-10-18 2022-10-21 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409840P 2016-10-18 2016-10-18
US62/409,840 2016-10-18
PCT/US2017/057106 WO2018075591A1 (en) 2016-10-18 2017-10-18 Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022169043A Division JP7478794B2 (ja) 2016-10-18 2022-10-21 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物

Publications (2)

Publication Number Publication Date
JP2019531745A true JP2019531745A (ja) 2019-11-07
JP2019531745A5 JP2019531745A5 (https=) 2020-11-26

Family

ID=62018862

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019520801A Pending JP2019531745A (ja) 2016-10-18 2017-10-18 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター
JP2022169043A Active JP7478794B2 (ja) 2016-10-18 2022-10-21 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022169043A Active JP7478794B2 (ja) 2016-10-18 2022-10-21 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物

Country Status (22)

Country Link
US (2) US10532099B2 (https=)
EP (1) EP3529363B1 (https=)
JP (2) JP2019531745A (https=)
KR (1) KR102604486B1 (https=)
CN (1) CN110036112B (https=)
AU (1) AU2017346788A1 (https=)
BR (1) BR112019007982A2 (https=)
CA (1) CA3040303A1 (https=)
CL (1) CL2019001054A1 (https=)
CO (1) CO2019004102A2 (https=)
CR (1) CR20190205A (https=)
DO (1) DOP2019000086A (https=)
EA (1) EA201990937A1 (https=)
EC (1) ECSP19031754A (https=)
IL (1) IL266011B2 (https=)
MA (1) MA46588A (https=)
MX (1) MX2019004518A (https=)
PE (1) PE20190840A1 (https=)
SG (1) SG11201903340TA (https=)
TN (1) TN2019000124A1 (https=)
UA (1) UA126860C2 (https=)
WO (1) WO2018075591A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023507142A (ja) * 2019-12-16 2023-02-21 オレゴン ヘルス アンド サイエンス ユニバーシティ 多重特異性ｔ細胞受容体

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3351636T (pt) 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
JP6483033B2 (ja) 2013-03-05 2019-03-13 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティＯｒｅｇｏｎ Ｈｅａｌｔｈ ＆ Ｓｃｉｅｎｃｅ Ｕｎｉｖｅｒｓｉｔｙ Ｔ細胞ターゲティングを調節することができるサイトメガロウイルスベクター
KR102403547B1 (ko) 2014-07-16 2022-05-30 오레곤 헬스 앤드 사이언스 유니버시티 외인성 항원을 포함하는 인간 시토메갈로바이러스
JP6816031B2 (ja) 2015-02-10 2021-01-20 オレゴン ヘルス アンド サイエンス ユニバーシティ 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
AU2016355468B2 (en) 2015-11-20 2022-12-15 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
CN110036112B (zh) 2016-10-18 2024-05-10 俄勒冈健康与科学大学 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体
US10632186B1 (en) 2019-03-21 2020-04-28 21C Bio Vaccine to pathogenic immune activation cells during infections
WO2020188111A1 (en) 2019-03-21 2020-09-24 21C Bio Vaccine to pathogenic immune activation cells during infections
US11077185B2 (en) 2019-03-21 2021-08-03 21C Bio Vaccine to pathogenic immune activation cells during infections
US12599658B2 (en) 2019-06-07 2026-04-14 Oregon Health & Science University Hepatitis B virus-specific T cell responses
JP2022536122A (ja) * 2019-06-07 2022-08-12 オレゴン ヘルス アンド サイエンス ユニバーシティ 腫瘍関連抗原特異的ｔ細胞応答
AU2020334061A1 (en) * 2019-08-20 2022-03-10 Oregon Health & Science University Modulation of T cell responses by UL18 of human cytomegalovirus
EP4021923A1 (en) * 2019-08-29 2022-07-06 VIR Biotechnology, Inc. Hepatitis b virus vaccines
WO2023034783A1 (en) 2021-08-31 2023-03-09 Vir Biotechnology, Inc. Tuberculosis vaccines
CA3226699A1 (en) 2021-08-31 2023-03-09 Vir Biotechnology, Inc. Recombinant hcmv vectors and uses thereof
WO2024121424A1 (en) 2022-12-09 2024-06-13 Daniel Zagury Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110188A1 (en) * 2002-07-16 2004-06-10 Gabriele Hahn Novel virus encoded chemokines determine the tissue tropism of human cytomegalovirus (HCMV)
WO2011143653A2 (en) * 2010-05-14 2011-11-17 Oregon Health & Science University Recombinant hcmv and rhcmv vectors and uses thereof
JP2012525141A (ja) * 2009-04-30 2012-10-22 フォンダツィオーネ セントロ サン ラファエレ デル モンテ タボール 遺伝子ベクター
WO2016011293A1 (en) * 2014-07-16 2016-01-21 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1988010311A1 (en) 1987-06-26 1988-12-29 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene and use thereof
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
EP1092775A1 (en) 1991-07-05 2001-04-18 American Cyanamid Company Methods for identifiying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus
WO1995003399A2 (en) 1993-07-19 1995-02-02 Cantab Pharmaceuticals Research Limited Production method for preparation of disabled viruses
ES2267101T3 (es) 1994-04-29 2007-03-01 PHARMACIA & UPJOHN COMPANY LLC Vacuna contra virus de inmunodeficiencia felina.
US5846806A (en) 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
ATE324435T1 (de) 1995-02-21 2006-05-15 Cantab Pharmaceuticals Res Ltd Virale zubereitungen, vektoren, immunogene und impfstoffe
EP0820311A4 (en) 1995-04-04 2002-09-25 Cell Genesys Inc TRANSPLANTATION OF GENETICALLY MODIFIED CELLS WITH LOW CLASS I PROTEIN RATES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX ON THEIR SURFACE
EP0966301B1 (en) 1996-07-31 2005-02-09 Ortho-McNeil Pharmaceutical, Inc. Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression
US20030138454A1 (en) 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
DE19733364A1 (de) 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
AU3910097A (en) 1997-08-05 1999-03-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Live recombinant vaccine comprising inefficiently or non-replicating vir us
US7204990B1 (en) 2000-11-28 2007-04-17 Medimmune Vaccines, Inc. Attenuation of cytomegalovirus virulence
CA2437201C (en) 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
AU2002247733B2 (en) 2001-02-21 2007-12-13 The Wistar Institute Of Anatomy And Biology Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
GB0122232D0 (en) 2001-09-14 2001-11-07 Medical Res Council Gene expression
IL160809A0 (en) 2001-09-20 2004-08-31 Glaxo Group Ltd HIV-gag CODON-OPTIMISED DNA VACCINES
US20030118568A1 (en) 2001-12-18 2003-06-26 Board Of Trustees Of The University Of Arkansas Viral stealth technology to prevent T cell-mediated rejection of xenografts
JP2005523942A (ja) 2002-04-30 2005-08-11 アヴィオル セラピューティクス インコーポレイテッド 免疫療法のためのアデノウイルスベクター
US7407744B2 (en) 2003-07-25 2008-08-05 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors
AU2005285513B2 (en) 2004-05-25 2011-02-24 Oregon Health And Science University SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
EP1602676A1 (en) 2004-06-01 2005-12-07 SOLVAY (Société Anonyme) Catalytic compositions
EP1799255A4 (en) 2004-06-25 2008-10-01 Medimmune Vaccines Inc RECOMBINANT HUMANESE CYTOMEGALOVIRUS AND HETEROLOGIST ANTIGENS CONTAINING VACCINES
WO2006125983A1 (en) 2005-05-23 2006-11-30 Oxxon Therapeutics Ltd Compositions for inducing an immune response against hepatitis b
AU2006284756B2 (en) 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2008112146A2 (en) 2007-03-07 2008-09-18 The Trustees Of The University Of Pennsylvania 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction
JP2010532764A (ja) 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
CN101889025B (zh) 2007-10-30 2013-11-13 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
US8883995B2 (en) 2009-03-06 2014-11-11 Icahn School Of Medicine At Mount Sinai Live attenuated influenza virus vaccines comprising microRNA response elements
WO2011076883A1 (en) 2009-12-23 2011-06-30 4-Antibody Ag Binding members for human cytomegalovirus
CN102844663B (zh) 2010-01-27 2016-01-06 俄勒冈健康科学大学 基于巨细胞病毒的免疫原性制剂
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
ES2679245T3 (es) 2010-05-05 2018-08-23 Sirion Biotech Gmbh Vacuna contra la infección por beta-herpesvirus y uso de la misma
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2013040320A1 (en) 2011-09-16 2013-03-21 Oregon Health & Science University Methods and kits used in identifying microrna targets
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
CA2890061A1 (en) 2012-12-04 2014-06-12 Merck Sharp & Dohme Corp. Conditional replicating viral vectors
JP6483033B2 (ja) 2013-03-05 2019-03-13 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティＯｒｅｇｏｎ Ｈｅａｌｔｈ ＆ Ｓｃｉｅｎｃｅ Ｕｎｉｖｅｒｓｉｔｙ Ｔ細胞ターゲティングを調節することができるサイトメガロウイルスベクター
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
JP6816031B2 (ja) 2015-02-10 2021-01-20 オレゴン ヘルス アンド サイエンス ユニバーシティ 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
AU2016355468B2 (en) 2015-11-20 2022-12-15 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
CA3028827A1 (en) * 2016-06-22 2017-12-28 Aeras Recombinant cytomegalovirus vectors as vaccines for tuberculosis
WO2018005559A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
CN110036112B (zh) 2016-10-18 2024-05-10 俄勒冈健康与科学大学 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110188A1 (en) * 2002-07-16 2004-06-10 Gabriele Hahn Novel virus encoded chemokines determine the tissue tropism of human cytomegalovirus (HCMV)
JP2012525141A (ja) * 2009-04-30 2012-10-22 フォンダツィオーネ セントロ サン ラファエレ デル モンテ タボール 遺伝子ベクター
WO2011143653A2 (en) * 2010-05-14 2011-11-17 Oregon Health & Science University Recombinant hcmv and rhcmv vectors and uses thereof
WO2016011293A1 (en) * 2014-07-16 2016-01-21 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOCHEM BIOPHYS RES COMMUN., vol. 386, no. 4, JPN6021031935, 2009, pages 549 - 553, ISSN: 0004803568 *
JOURNAL OF CLINICAL INVESTIGATION, vol. 120, no. 10, JPN6021031936, 2010, pages 3641 - 3650, ISSN: 0004572432 *
MOLECULAR AND CELLULAR BIOLOGY, vol. 34, no. 20, JPN6021031932, 2014, pages 3780 - 3787, ISSN: 0004572435 *
ONCOTARGET, vol. 7, no. 24, JPN7021003248, 2 May 2016 (2016-05-02), pages 36614 - 36621, ISSN: 0004572434 *
SCIENCE, vol. 351, no. 6274, JPN6021031937, 12 February 2016 (2016-02-12), pages 714 - 720, ISSN: 0004572431 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023507142A (ja) * 2019-12-16 2023-02-21 オレゴン ヘルス アンド サイエンス ユニバーシティ 多重特異性ｔ細胞受容体

Also Published As

Publication number Publication date
US20200237915A1 (en) 2020-07-30
DOP2019000086A (es) 2019-07-31
IL266011B1 (en) 2023-11-01
EP3529363A1 (en) 2019-08-28
KR20190064624A (ko) 2019-06-10
ECSP19031754A (es) 2019-05-31
CA3040303A1 (en) 2018-04-26
JP2023002716A (ja) 2023-01-10
AU2017346788A1 (en) 2019-05-02
CO2019004102A2 (es) 2019-07-10
AU2017346788A8 (en) 2019-05-16
BR112019007982A2 (pt) 2019-07-02
IL266011A (en) 2019-06-30
CN110036112B (zh) 2024-05-10
WO2018075591A8 (en) 2019-04-04
WO2018075591A1 (en) 2018-04-26
CL2019001054A1 (es) 2019-09-27
PE20190840A1 (es) 2019-06-17
CN110036112A (zh) 2019-07-19
EA201990937A1 (ru) 2019-09-30
MX2019004518A (es) 2019-06-17
TN2019000124A1 (en) 2020-10-05
US20180133321A1 (en) 2018-05-17
CR20190205A (es) 2020-01-07
UA126860C2 (uk) 2023-02-15
JP7478794B2 (ja) 2024-05-07
MA46588A (fr) 2021-04-14
EP3529363A4 (en) 2020-05-06
SG11201903340TA (en) 2019-05-30
IL266011B2 (en) 2024-03-01
US11305015B2 (en) 2022-04-19
US10532099B2 (en) 2020-01-14
KR102604486B1 (ko) 2023-11-22
EP3529363B1 (en) 2025-07-30

Similar Documents

Publication Publication Date Title
JP7478794B2 (ja) 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物
JP7133468B2 (ja) マイクロｒｎａ認識エレメントを含むｃｍｖベクター
JP6816031B2 (ja) 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
JP2025131719A (ja) ヒトサイトメガロウイルスのｕｌ１８によるｔ細胞応答の調節
EA042630B1 (ru) Цитомегаловирусные векторы, выбирающие t-клетки, ограниченные по молекулам главного комплекса гистосовместимости e
OA19584A (en) Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
HK40011160A (en) Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
HK40073534A (en) Modulation of t cell responses by ul18 of human cytomegalovirus
HK1260171A1 (en) Cmv vectors comprising microrna recognition elements

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201014

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220621